Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data

Irini Chatziralli(National Health Service), Sobha Sivaprasad(Moorfields Eye Hospital), Martina Santarelli(National Health Service), Namritha Patrao(Moorfields Eye Hospital), Luke Nicholson(Moorfields Eye Hospital NHS Foundation Trust), Marta Zola(National Health Service), Ranjan Rajendram(University College London), Philip Hykin(Moorfields Eye Hospital)
Eye
June 16, 2017
10.1038/eye.2017.111
Cited by 24

Related Papers

Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes
|JAMA|2017|2.3k
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
|Ophthalmology|2010|510
Circulating MicroRNAs as Novel Biomarkers for Platelet Activation
|Circulation Research|2013|396
Large language models and their impact in ophthalmology
|The Lancet Digital Health|2023|158
Patterns of Peripheral Retinal and Central Macula Ischemia in Diabetic Retinopathy as Evaluated by Ultra-widefield Fluorescein Angiography
|American Journal of Ophthalmology|2014|142